(Updates with company statement, paragraphs 4-7)
March 26 Some bottles of Alli, GlaxoSmithKline
Plc's weight-loss drug sold over the counter in the
United States, have been tampered with, and the Food and Drug
Administration was investigating, the company said on Wednesday.
Consumers have reported that about 20 bottles bought in
stores in seven mostly Southern states contained products other
than the drug, GlaxoSmithKline said.
The company said the affected bottles from five lots of the
drug could contain tablets and capsules of different shapes and
colors. The actual drug is colored turquoise. The bottles could
be unlabeled and the lot numbers might not match the numbers on
the carton, GlaxoSmithKline said.
Glaxo spokeswoman Deborah Bolding said that so far there
have been no reports of serious illness related to the products.
The company has advised anyone who did take pills found to come
from packages that had been tampered with to contact their
"We are doing an investigation to determine any further
action," she said in a telephone interview.
FDA spokeswoman Tara Goodin confirmed by phone that the
regulatory agency was also investigating the tampering.
Alli, which is sold by Glaxo's consumer healthcare business,
is approved for use without a prescription for overweight
adults, in conjunction with a low-fat diet.
Glaxo said the affected bottles were found in Alabama,
Florida, Louisiana, Mississippi, New York, North Carolina and
(Reporting By Vrinda Manocha and Deena Beasley; Editing by Ted
Kerr and Jonathan Oatis)